You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Express Scripts
McKinsey
Merck
Harvard Business School

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FASLODEX

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Faslodex

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT00099437 Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. Active, not recruiting AstraZeneca Phase 3 2005-02-01 The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment.
New Dosage NCT01300351 Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women Completed AstraZeneca Phase 3 2011-03-01 The purpose of this study is to evaluate the efficacy of a new dose of 500mg Fulvestrant with the standard dose of 250mg in Chinese postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed a prior endocrine treatment.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Faslodex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006903 Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Active, not recruiting AstraZeneca Phase 2 2004-08-01 RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer.
NCT00006903 Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Active, not recruiting National Cancer Institute (NCI) Phase 2 2004-08-01 RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer.
NCT00006903 Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Active, not recruiting Gynecologic Oncology Group Phase 2 2004-08-01 RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer.
NCT00010153 ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer Terminated Breast International Group Phase 3 2000-11-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 before surgery may block the uptake of estrogen by the tumor cells and prevent metastases. It is not yet known if ICI 182780 is effective in preventing breast cancer metastases. PURPOSE: Randomized phase III trial to study the effectiveness of ICI 182780 given before surgery in treating women who have stage I or stage II primary breast cancer.
NCT00010153 ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer Terminated European Organisation for Research and Treatment of Cancer - EORTC Phase 3 2000-11-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 before surgery may block the uptake of estrogen by the tumor cells and prevent metastases. It is not yet known if ICI 182780 is effective in preventing breast cancer metastases. PURPOSE: Randomized phase III trial to study the effectiveness of ICI 182780 given before surgery in treating women who have stage I or stage II primary breast cancer.
NCT00012025 ICI 182780 in Treating Women With Metastatic Breast Cancer Completed National Cancer Institute (NCI) Phase 2 2001-05-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 may fight breast cancer by blocking the activity of estrogen in the tumor cells. PURPOSE: Phase II trial to study the effectiveness of ICI 182780 in treating patients who have metastatic breast cancer that has not responded to previous hormone therapy.
NCT00012025 ICI 182780 in Treating Women With Metastatic Breast Cancer Completed Alliance for Clinical Trials in Oncology Phase 2 2001-05-01 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 may fight breast cancer by blocking the activity of estrogen in the tumor cells. PURPOSE: Phase II trial to study the effectiveness of ICI 182780 in treating patients who have metastatic breast cancer that has not responded to previous hormone therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Faslodex

Condition Name

Condition Name for Faslodex
Intervention Trials
Breast Cancer 43
Metastatic Breast Cancer 21
Breast Neoplasms 11
Stage IV Breast Cancer 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Faslodex
Intervention Trials
Breast Neoplasms 111
Carcinoma 9
Neoplasms 8
Carcinoma, Non-Small-Cell Lung 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Faslodex

Trials by Country

Trials by Country for Faslodex
Location Trials
United States 428
Italy 75
Canada 43
Spain 37
Japan 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Faslodex
Location Trials
Texas 25
California 24
Florida 22
New York 21
Missouri 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Faslodex

Clinical Trial Phase

Clinical Trial Phase for Faslodex
Clinical Trial Phase Trials
Phase 4 2
Phase 3 24
Phase 2 71
[disabled in preview] 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Faslodex
Clinical Trial Phase Trials
Completed 33
Not yet recruiting 31
Active, not recruiting 27
[disabled in preview] 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Faslodex

Sponsor Name

Sponsor Name for Faslodex
Sponsor Trials
AstraZeneca 46
National Cancer Institute (NCI) 17
Pfizer 13
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Faslodex
Sponsor Trials
Other 104
Industry 98
NIH 18
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Merck
Johnson and Johnson
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.